Sucralfin

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sucralfin

What is Sucralfin?

Sucralfin is a gastroprotective medication used primarily to treat and manage various inflammatory and ulcerative conditions of the upper gastrointestinal tract. It belongs to a class of drugs known as cytoprotective agents, which work by creating a physical barrier over damaged mucosal tissue rather than by altering the chemical balance of stomach acid.

Mechanism of Action

The active component of Sucralfin is sucralfate, a complex salt composed of aluminum hydroxide and sulfated sucrose. Unlike antacids or proton pump inhibitors that neutralize or suppress acid production, Sucralfin acts locally at the site of injury.

In the presence of an acidic environment, the substance undergoes a structural change, becoming a highly viscous, paste-like gel. This gel has a strong affinity for exposed proteins found in ulcer craters, such as albumin and fibrinogen. By binding to these proteins, it forms a protective coating that shields the injured area from further erosion caused by gastric acid, pepsin, and bile salts.

Therapeutic Role

By providing a mechanical buffer, Sucralfin allows the underlying tissue to recover and undergo natural repair processes. In addition to its barrier function, the medication is thought to support the body's own mucosal defenses by:

  • Promoting the local production of prostaglandins, which help protect the stomach lining.
  • Binding to growth factors, potentially concentrating them at the site of the ulcer to facilitate tissue regeneration.
  • Increasing the thickness and viscosity of the natural mucous layer.

Sucralfin is utilized in the management of duodenal ulcers and is sometimes employed in the treatment of gastric ulcers and certain forms of gastritis. Because it is minimally absorbed into the bloodstream, its effects are largely confined to the lining of the digestive tract.

Regulatory References

  1. Sucralfate: MedlinePlus Drug Information

What side effects are possible with Sucralfin?

Possible Side Effects and Safety Information

The safety profile for Sucralfin (Sucralfate) is primarily characterized by adverse effects related to the gastrointestinal system, which is consistent with its local mechanism of action as a mucosal protective agent. Side effects are classified based on frequency reported in official regulatory documents.

Documented Adverse Reactions

The most frequently reported adverse reaction in clinical trials, classified as Common in regulatory labeling, is Constipation. Other less frequent effects, classified as Uncommon, may involve the Nervous System (e.g., Dizziness, Sleepiness) or the Skin (e.g., Pruritus, Rash).

Serious Adverse Reactions

The official labeling documents potential for serious, though rare, adverse events. These include generalized Hypersensitivity Reactions, such as Anaphylactic reactions, angioedema, and urticaria. Furthermore, reports of Bezoar Formation—a physical mass in the digestive tract—have been documented, primarily in patients with predisposing conditions such as delayed gastric emptying.

Specific Safety Considerations

A critical safety consideration stems from the drug's composition as an aluminum complex. In patients with impaired renal function (including those on dialysis), the ability to excrete absorbed aluminum is compromised, posing a risk of aluminum accumulation and subsequent toxicity. For this reason, caution is advised for use in patients with chronic renal impairment. Regulatory authorities also note that the safety and effectiveness in pediatric patients have not been established. Additionally, Sucralfin has the potential to reduce the absorption of other orally administered medicines by binding to them in the stomach.

Overdose and Emergency Response

Sucralfin Overdose and When to Seek Help

Official regulatory information indicates that the risks associated with acute overdosage of Sucralfin (Sucralfate) are minimal. This is primarily because the medication is only minimally absorbed from the gastrointestinal tract and acts locally.

Documented Overdose Presentations

In the rare reports describing human overdosage, most individuals remained asymptomatic. When adverse events were described, they were generally confined to the gastrointestinal system and included symptoms such as dyspepsia, abdominal pain, nausea, and vomiting.

Overdose Risk & Absorption
Minimal systemic absorption of Sucralfin
Acute oral studies in animals using high doses (up to 12 g/kg body weight) did not identify a lethal dose

Emergency Actions and Treatment

Due to the limited systemic absorption and the lack of severe toxicity observed in regulatory data, no specific treatment recommendations can be given for an acute sucralfin overdosage. The official regulatory stance is that the minimal absorption capacity results in minimal risk.

Individuals who suspect an overdose or who experience concerning symptoms should contact emergency medical services or a poison control center for evaluation and guidance.

Population Considerations

No population-specific instructions or risks directly related to acute overdosage are detailed in the official overdose sections. However, in non-overdose safety sections, caution regarding aluminum accumulation is noted for patients with chronic renal failure or those on dialysis, as sucralfin contains aluminum.

Therapeutic Uses of Sucralfin

Quick Facts: Sucralfin

  • Active Duodenal Ulcers: May be prescribed for the short-term management of active duodenal ulcers.
  • Recurrence: It is also used for the long-term maintenance of duodenal ulcers after healing, to help prevent their return.
  • Esophagus: May be indicated to help manage symptoms of gastroesophageal reflux disease (GERD).

Sucralfin is a prescription medication utilized to help manage and treat specific conditions within the gastrointestinal tract. Its primary approved use is for the short-term treatment of active duodenal ulcers (ulcers in the first part of the small intestine), typically for a period up to eight weeks. Sucralfin may help facilitate the healing process of these ulcers.

After an acute ulcer has healed, the medication is also often prescribed for a longer duration as maintenance therapy. This is intended to help reduce the rate of recurrence of duodenal ulcers. By aiding in the protection of the damaged mucosal lining, Sucralfin helps to create conditions where healing may occur.

In addition to its main use, Sucralfin may also be used in clinical practice to help manage symptoms associated with gastroesophageal reflux disease (GERD) and other inflammatory conditions of the upper GI tract. This medication is not absorbed systemically and works locally at the site of damage. Discussion with a healthcare provider is recommended to determine if this is a suitable treatment option.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Sucralfin — official regulatory information

Category Official Regulatory Statement
Populations for whom use is allowed (as stated in label): Adults are eligible for standard use for labeled indications.
Populations for whom use is not recommended (if applicable): Pediatric patients are not recommended for use as safety and effectiveness have not been established in this population.
Populations for whom use is contraindicated: Patients with known hypersensitivity reactions to the active substance, sucralfate, or to any of the product's excipients.
Age-related eligibility rules: Pediatric Use: Safety and effectiveness have not been established. Geriatric Use: Dose selection should be cautious and may require starting at the low end of the dosing range, due to the greater frequency of decreased renal function.
Condition-specific eligibility rules: Use with caution in patients with chronic renal failure or those receiving dialysis due to potential aluminum accumulation. Caution is also warranted in patients with conditions that may predispose to bezoar formation, such as delayed gastric emptying.
Pregnancy and lactation eligibility status (if explicitly documented): Pregnancy: Use is permitted only if clearly needed (FDA Pregnancy Category B). Lactation: Caution should be exercised when administered to a nursing woman, as it is unknown if the drug is excreted in human milk.

Eligibility Classifications (High-Level)

Classification Official Regulatory Wording
Eligibility severity classification (as defined in official documents): Contraindicated (Hypersensitivity); Use with Caution (Renal Impairment, Bezoar risk); Safety/Effectiveness Not Established (Pediatric Use).

Resulting Eligibility Structure

Official eligibility statements:

  • The medicine is contraindicated for patients with a known hypersensitivity reaction to sucralfate or any of its excipients.
  • Safety and effectiveness have not been established for use in pediatric patients.
  • Use must be with caution in patients with chronic renal failure or those receiving dialysis due to the risk of aluminum accumulation.

Connection to the overall eligibility profile: The regulatory profile defines Sucralfin primarily for the adult population, with hypersensitivity as the single absolute prohibition for use. Due to the aluminum component, the profile mandates caution in patients with chronic kidney disease or those on dialysis, creating a restricted-use category. The official labeling explicitly states that pediatric use is not established, defining the limitations for use in children.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Sucralfin (Sucralfate) exhibits an official interaction profile defined primarily by a nonsystemic pharmacokinetic interaction that occurs within the gastrointestinal tract.

Official Interaction Statements

Interaction Type Interacting Substances and Requirements
Reduced Absorption Co-administration may reduce the extent of absorption (bioavailability) of several medicines, including digoxin, phenytoin, theophylline, ketoconazole, and fluoroquinolone antibiotics (e.g., ciprofloxacin, ofloxacin).
Timing Restriction Due to the absorption interaction, numerous concomitant medications require administration to be separated, typically by administering the other drug 2 hours before Sucralfin.
Increased Aluminum Burden As an aluminum complex, co-administration with other aluminum-containing products (like antacids) increases the total body burden of aluminum. Antacids must not be taken within 30 minutes before or after Sucralfin.

Population-Specific Interaction Notes

Regulatory documentation highlights specific interaction risks for certain populations. Chronic Renal Failure and Dialysis Patients are noted to be at risk for aluminum accumulation and toxicity (such as encephalopathy) because of impaired aluminum excretion. Additionally, close monitoring of blood sugar is specified for diabetic patients due to reported episodes of hyperglycemia.

Mechanism of Action

Sucralfin's mechanism of action is primarily localized and physicochemical, involving two distinct mechanistic domains.

Site-Specific Polymerization and Chemical Adherence

Within the acidic environment of the stomach, the compound undergoes polymerization to form a highly viscous, negatively charged substance. This activated material exhibits a chemical affinity for proteins, specifically those with a positive charge, which are exposed at the base of mucosal discontinuities (ulcers or erosions). Chemical binding to these exposed proteins forms a protective, adherent barrier that shields the tissue from aggressive luminal hydrolytic and acidic factors. This shielding action helps maintain conditions suitable for natural epithelial restoration.

Modulation of Local Humoral Regulators

Beyond the physical barrier, the drug engages local signaling pathways to affect the mucosal regulatory system. This involves promoting the local release of cytoprotective mediators, including prostaglandins and growth factors, within the tissue. This action influences the local production of mucus and bicarbonate, resulting in modulation of the mucosal barrier properties and local vascular dynamics, which supports the local homeostatic balance of regenerative processes.

Dosage and Administration Information

How Sucralfin (Sucralfate) is Used

Sucralfin is administered exclusively via the oral route as either a 1 gram tablet or a 1 gram per 10 mL oral suspension. The fundamental principle guiding its use is the need to administer the drug on an empty stomach to maximize contact with the gastrointestinal lining. This medication is not significantly absorbed into the bloodstream; its function is localized, making precise timing essential for correct use.


Standard Adult Dosing and Administration Timing

Dosing regimens are prescribed based on the specific treatment goal.

Treatment Goal Dose Frequency Duration Pattern
Active Duodenal Ulcer 1 gram Four times daily (QID) Typically 4 to 8 weeks
Ulcer Maintenance Therapy 1 gram Twice daily (BID) Up to one year

Each dose must be taken on an empty stomach, generally one hour before meals and then a final dose at bedtime. The oral suspension formulation requires shaking well before use.


Critical Administration Conditions

For proper use, Sucralfin must be separated from other orally administered agents. To prevent altered bioavailability, other oral medications should be taken at least two hours before Sucralfin. Additionally, antacids must not be consumed within one-half hour before or after a Sucralfin dose.

Population-Specific Use

Dosage selection for older adults should be cautious, often starting at the lower end of the recommended range, a practice advised due to the higher prevalence of decreased organ function. Official labeling indicates that safety and effectiveness have not been established for use in pediatric patients.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research on Primary Indication: Gastrointestinal Ulceration

Clinical trials primarily evaluated Sucralfin for its effect on healing active duodenal and gastric ulcers. Initial studies reported that the majority of patients receiving the treatment achieved complete ulcer healing after 4 to 8 weeks, with efficacy generally comparable to some H2-receptor antagonists in achieving symptomatic improvement and mucosal healing. Maintenance studies explored its use at lower doses to prevent the recurrence of healed duodenal ulcers.

Studies have investigated the drug's effect on neurotransmitter activity. Research measured outcomes in symptom severity over a 12-week period in a randomized, placebo-controlled setting. The primary endpoint investigated was the change in the Visual Analogue Scale (VAS) score from baseline.

Parameter Investigated Key Finding in Studies
Absorption/Metabolism Minimal systemic absorption (approx. 5%) following oral dosing; primary action is local.
Anti-inflammatory Effect Studied against a placebo in initial trials focusing on specific mucosal conditions.

Safety and Patient Populations

Studies have examined outcomes in adults across multiple indications, including peptic ulcer disease and reflux esophagitis. Individuals with renal impairment were generally excluded from trials, as the drug contains aluminum. Long-term studies report that the product is generally well tolerated, with constipation being the most frequently reported side effect (occurring in approximately 1% to 10% of patients).

Secondary/Exploratory Findings

An exploratory trial examined findings in refractory cases of a related condition. A study observed a 60% response rate in the target population, based on a specific composite clinical score. Evidence remains limited regarding long-term outcomes (beyond one year) in this secondary use. Recent research has also studied its effectiveness when used topically for managing epithelial wounds, such as chronic ulcers and mucositis, demonstrating its potential role in wound healing based on systematic reviews.

Frequently Asked Questions (FAQ)

Common questions about Sucralfin (FAQ)


Q: Is Sucralfin the same type of medicine as [Common Similar Drug Name]?

Official product information describes Sucralfin as a gastrointestinal protectant that works locally on the lining of the digestive tract. Its primary action is to form a physical protective barrier over ulcers, and it is minimally absorbed into the bloodstream. This local mechanism is generally described as distinct from systemic treatments that focus on suppressing acid production.


Q: How quickly does Sucralfin usually start working?

Regulatory documents indicate that Sucralfin works by binding immediately at the ulcer site to form a protective coating. While this physical barrier forms right away, clinical studies primarily track the time required for complete ulcer healing, which typically takes between four and eight weeks.


Q: Is it normal to feel [mild, common symptom, e.g., slightly bloated] after starting Sucralfin?

The official documentation states that the most frequently reported adverse reaction in studies is constipation. While not the most common, other reported gastrointestinal effects include dry mouth, flatulence, gastric discomfort, indigestion, nausea, and vomiting. If a patient experiences new or persistent discomfort, they typically discuss this with a healthcare provider.


Q: Are there any long-term health concerns associated with using Sucralfin?

Official labeling highlights specific long-term concerns for certain groups. Because Sucralfin is an aluminum complex, chronic use carries a documented risk of aluminum accumulation and toxicity (such as encephalopathy) in patients with impaired renal function (kidney disease) or those undergoing dialysis.


Q: Is there a different Sucralfin product for children?

The official regulatory documents explicitly state that the safety and effectiveness of Sucralfin have not been established in pediatric patients. For this reason, regulatory agencies do not reference a specific product or dose for use in children.


Q: Does Sucralfin interact with common supplements like vitamin D or calcium?

Official product information states that Sucralfin may reduce the systemic absorption of various other oral medicines by binding to them in the stomach. To manage potential interference, regulatory guidelines generally recommend administering other oral medications two hours before using Sucralfin.


Q: Can Sucralfin be used alongside blood pressure medicines?

Official regulatory warnings note that Sucralfin can reduce the absorption of certain oral medications, including drugs such as digoxin. Regulatory documents state that when other critical oral medications are taken, such as those for blood pressure, the other medication is generally taken two hours before Sucralfin to minimize potential absorption changes.


Q: Does Sucralfin affect the absorption of food or nutrients?

Regulatory instructions emphasize that the medication is required on an empty stomach, typically one hour before meals. This timing is standard practice to ensure maximum local contact for forming its protective layer, which suggests that food may interfere with the drug’s action.


Q: Does Sucralfin change the color or frequency of bowel movements?

The most frequent adverse reaction reported for Sucralfin is constipation, which affects the frequency of bowel movements. Official labeling also reports diarrhea as a less common gastrointestinal effect. Changes in the color of stool are not specifically documented in the regulatory labeling.


Q: How do medical professionals assess if Sucralfin is working?

Regulatory information indicates that treatment is typically continued for the prescribed duration unless healing has been demonstrated. Official documentation cites methods such as X-ray or endoscopic examination as ways to confirm ulcer healing, in addition to observing symptomatic relief.


Q: What if I forget to use Sucralfin sometimes?

Patient information derived from regulatory documents advises that if a dose is missed, it can be taken as soon as it is remembered. If the time is near the next scheduled use, the common practice described in patient information is to omit the forgotten amount and continue with the next scheduled time.


Q: Is Sucralfin a type of antibiotic?

Official documentation classifies Sucralfin as a gastrointestinal agent and an antiulcer agent. It is not classified as an antibiotic. However, the label does note that the medicine can interact with certain types of antibiotics, which requires a time separation between doses.


Q: What is the difference between a side effect and an allergic reaction to Sucralfin?

Regulatory labeling differentiates between common adverse reactions (side effects) such as constipation, and rare but serious hypersensitivity reactions (allergic reactions). Serious allergic reactions documented include anaphylaxis, angioedema (swelling), and urticaria (hives).


Q: Is it normal for Sucralfin to taste sweet or chalky?

Official product information describes the liquid form of Sucralfin (oral suspension) as a pink suspension with cherry flavor. The taste and texture of the tablet form are not specified in the regulatory description.


How should Sucralfin be stored and disposed of?

Storage and Disposal of Sucralfin (Sucralfate)

The storage and handling of Sucralfin must adhere strictly to regulatory requirements to maintain product stability and safety, as outlined in official labeling.

Storage Requirements

Sucralfin must be stored at a Controlled Room Temperature, which is defined as 20 C to 25 C (68 F to 77 F). It is essential to avoid freezing the medication, especially the liquid suspension, and to protect it from excessive heat, moisture, and direct light. The container must be kept tightly closed when not in use. As a standard safety measure, the product must be stored out of the reach of children.

Disposal Instructions

Unused or expired Sucralfin must be disposed of according to official guidelines. The preferred method is utilizing a local drug take-back program. If no such program is available, the product should not be flushed down a toilet or sink. Instead, the medication should be removed from its container, mixed with an undesirable substance (like coffee grounds), placed in a sealed bag, and discarded in the household trash. Identifying information should be removed from the container before disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sucralfin found in:

A-Z Index: